PRIMA-1

CAS No. 5608-24-2

PRIMA-1( PRIMA 1 | PRIMA1 )

Catalog No. M15042 CAS No. 5608-24-2

A specific mutant p53 reactivator that induces apoptosis and enhances chemotherapeutic cytotoxicity in cancer cell lines.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 42 In Stock
10MG 60 In Stock
25MG 129 In Stock
50MG 195 In Stock
100MG 348 In Stock
200MG 518 In Stock
500MG 831 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    PRIMA-1
  • Note
    Research use only, not for human use.
  • Brief Description
    A specific mutant p53 reactivator that induces apoptosis and enhances chemotherapeutic cytotoxicity in cancer cell lines.
  • Description
    A specific mutant p53 reactivator that induces apoptosis and enhances chemotherapeutic cytotoxicity in cancer cell lines; is efficacious against myeloma cells with differential p53 genotypes, causes the demethylation of TP73, through DNMT1 depletion, to subsequently enhance UPR; selectively induces apoptosis and cell cycle arrest in p53 mutant cells compared to CAPAN-2 cells.Blood Cancer Phase 2 Clinical.
  • In Vitro
    The cell lines are cultured in the presence of PRIMA-1 (NSC-281668) at 0-140 μM. The IC50s are 35, 40, 50, 50, 60, 70 and 75 μM for PANC-1, HEC-1-B, SUM149, AN 3CA, Ishikawa, Panc02 and MDA-MB-231 cells, respectively.
  • In Vivo
    PRIMA-1 (Prima-1) is a p53-modulating agent. 150 or 300 ppm PRIMA-1 significantly suppresses (P<0.0001) lung adenocarcinoma formation by 56% and 62%, respectively, after 17 weeks and 39% and 56%, respectively, after 34 weeks. Administration of 150 or 300 ppm PRIMA-1 significantly suppresses NNK-induced total lung adenocarcinoma formation by 57% or 62% (P<0.0001), respectively, after 17 weeks of exposure and by 39% or 56% (P<0.0001), respectively, after 34 weeks of exposure. As with administration of the lower (50 ppm) dose of CP-31398, administration of the lower (150 ppm) dose of PRIMA-1also slightly increases the number of NNK-induced lung adenomas.
  • Synonyms
    PRIMA 1 | PRIMA1
  • Pathway
    Apoptosis
  • Target
    MDM2-p53
  • Recptor
    p53
  • Research Area
    Cancer
  • Indication
    Blood cancer

Chemical Information

  • CAS Number
    5608-24-2
  • Formula Weight
    185.2203
  • Molecular Formula
    C9H15NO3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 44 mg/mL
  • SMILES
    O=C1C(CO)(CO)N2CCC1CC2
  • Chemical Name
    1-Azabicyclo[2.2.2]octan-3-one, 2,2-bis(hydroxymethyl)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Izetti P, et al. Invest New Drugs. 2014 Oct;32(5):783-94. 2. Bykov VJ, et al. Carcinogenesis. 2002 Dec;23(12):2011-8. 3. Teoh PJ, et al. Oncotarget. 2016 Sep 20;7(38):61806-61819.
molnova catalog
related products
  • COTI-2

    COTI-2 (COTI2) is an orally available thiosemicarbazone that may act on mutant forms of p53 and PI3K/AKT/mTOR pathway.

  • RITA

    RITA(NSC 652287) induced both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks. RITA, a drug that, like nutlin-3, can disrupt the p53/Mdm2 interaction.

  • UC2288

    UC2288 is a relatively selective p21 attenuator which is synthesized based Sorafenib. UC2288 attenuates p21 protein levels with minimal effect on p21 protein stability.